Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Differentiation of Common Myeloid Progenitor Cells01:15

Differentiation of Common Myeloid Progenitor Cells

Common myeloid progenitors (CMPs) are oligopotent cells that can differentiate into granulocytes and macrophages. Granulocytes and macrophages are essential for protecting the body against bacterial, viral, or fungal infections. They migrate from the bone marrow into the circulating blood to reach specific tissue sites where they differentiate and help in immune surveillance. However, they survive only for a few days and must be continuously made available to the organism to maintain a robust...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Author response to "Physical activity - Even at high volumes - Is associated with a lower risk of colon cancer" by Erika Rees-Punia and Alpa V. Patel.

Cancer epidemiology·2026
Same author

Bispecific Antibodies in Multiple Myeloma: A Concise Review of Current Treatments.

Cancer investigation·2026
Same author

Unlocking <i>KRAS</i>: Navigating Its Molecular Biology and Treatment Landscape Among Gastrointestinal Malignancies.

Current oncology (Toronto, Ont.)·2026
Same author

Targeted Therapies in Non-Small Cell Lung Cancer: A Contemporary Review.

American journal of clinical oncology·2025
Same author

CRE25-033: A MET Amplified Metastatic Esophageal Adenocarcinoma Demonstrates Response to the MET Inhibitor Capmatinib.

Journal of the National Comprehensive Cancer Network : JNCCN·2025
Same author

Bruton Tyrosine Kinase Degraders: Current Concepts.

American journal of clinical oncology·2025

Related Experiment Video

Updated: Jun 30, 2026

Flow Cytometry to Estimate Leukemia Stem Cells in Primary Acute Myeloid Leukemia and in Patient-derived-xenografts, at Diagnosis and Follow Up
09:01

Flow Cytometry to Estimate Leukemia Stem Cells in Primary Acute Myeloid Leukemia and in Patient-derived-xenografts, at Diagnosis and Follow Up

Published on: March 26, 2018

Hairy cell leukemia: current concepts.

Timothy Cannon1, Dalia Mobarek, Julia Wegge

  • 1Division of Hematology/Oncology, George Washington University Medical Center, Washington, DC, USA.

Cancer Investigation
|September 18, 2008
PubMed
Summary

Hairy cell leukemia (HCL) is a rare B-cell neoplasm affecting males more than females. Advances in purine analogue treatments have significantly improved patient prognosis and remission rates.

Area of Science:

  • Hematology
  • Oncology
  • Immunology

Background:

  • Hairy cell leukemia (HCL) is a chronic lymphoproliferative disorder and a mature B-cell neoplasm.
  • It accounts for 2-3% of leukemia cases, with approximately 600 new U.S. diagnoses annually.
  • HCL predominantly affects males, with a median age of onset at 52 years, and is more common in Caucasians.

Purpose of the Study:

  • To provide a comprehensive overview of Hairy Cell Leukemia.
  • To discuss the characteristic features, epidemiology, and clinical manifestations of HCL.
  • To highlight the impact of recent treatment advancements on patient outcomes.

Main Methods:

  • Review of WHO classification for HCL diagnosis.
  • Analysis of epidemiological data regarding HCL incidence and demographics.

More Related Videos

A Detailed Protocol for Characterizing the Murine C1498 Cell Line and its Associated Leukemia Mouse Model
08:00

A Detailed Protocol for Characterizing the Murine C1498 Cell Line and its Associated Leukemia Mouse Model

Published on: October 14, 2016

From a 2DE-Gel Spot to Protein Function: Lesson Learned From HS1 in Chronic Lymphocytic Leukemia
10:18

From a 2DE-Gel Spot to Protein Function: Lesson Learned From HS1 in Chronic Lymphocytic Leukemia

Published on: October 19, 2014

Related Experiment Videos

Last Updated: Jun 30, 2026

Flow Cytometry to Estimate Leukemia Stem Cells in Primary Acute Myeloid Leukemia and in Patient-derived-xenografts, at Diagnosis and Follow Up
09:01

Flow Cytometry to Estimate Leukemia Stem Cells in Primary Acute Myeloid Leukemia and in Patient-derived-xenografts, at Diagnosis and Follow Up

Published on: March 26, 2018

A Detailed Protocol for Characterizing the Murine C1498 Cell Line and its Associated Leukemia Mouse Model
08:00

A Detailed Protocol for Characterizing the Murine C1498 Cell Line and its Associated Leukemia Mouse Model

Published on: October 14, 2016

From a 2DE-Gel Spot to Protein Function: Lesson Learned From HS1 in Chronic Lymphocytic Leukemia
10:18

From a 2DE-Gel Spot to Protein Function: Lesson Learned From HS1 in Chronic Lymphocytic Leukemia

Published on: October 19, 2014

  • Summary of clinical presentation and pathological features of HCL.
  • Evaluation of treatment outcomes with purine analogues.

    • Main Results:

    • Hairy cells are distinct clonal B cells with characteristic morphology and surface markers (CD103, CD22, CD11c).
    • Common clinical presentations include splenomegaly and pancytopenia, with potential complications like infections and vasculitis.
    • Purine analogue therapies (Cladribine, Pentostatin) have led to significant improvements in response rates and durable remissions.

    Conclusions:

    • Hairy cell leukemia, while historically fatal, now has a significantly improved prognosis due to effective treatments.
    • Modern therapies offer high response rates and long-lasting remissions for HCL patients.
    • Continued research into HCL pathogenesis and treatment remains crucial.